NICE guidance framework: Relevant NICE recommendations include: CG189 (Obesity: identification, assessment and management) includes bariatric surgery indications and follow-up principles NG28 (Type 2 diabetes in adults) supports GLP-1 agonist use for glycaemic control and weight management in suitable patients with diabetes TA875 (Semaglutide for managing weight) recommends semaglutide 2.4mg (Wegovy) for adults with at least one weight-related condition and a BMI of at least 35 kg/m (or 30 kg/m for certain ethnic groups), within specialist weight management services [2] Post-bariatric medication principles: NHS bariatric services typically follow these principles when considering additional medications: Timing generally not initiated until weight stabilisation occurs, which varies between centres Indication clear clinical need, such as significant weight regain, inadequate initial weight loss, or persistent comorbidities Multidisciplinary assessment review by bariatric team including surgeon, physician, dietitian, and psychologist Nutritional optimisation ensuring adequate vitamin and mineral status before initiating appetite-suppressing medications Monitoring protocols regular follow-up for efficacy, adverse effects, and nutritional parameters Prescribing considerations: Ozempic is currently licensed for type 2 diabetes , not obesity alone
Working with a treatment professional, you can try different strategies and document your physical, mental, and emotional reactions to determine what is best for you
Ready to Explore GLP-1 Therapy
For now we dont have that information with GLP-1 products, but we are collecting the information so we will see. If in 2026 and 2027 we collect information that shows that GLP-1 agonist semaglutides (weight loss drugs) are being abused in sport, they could be banned before the Los Angeles Olympics, he confirmed
This allows the body to slowly adapt to the medication before increasing the injection dosage
